MARKET

CALC

CALC

CALCIMEDICA INC
NASDAQ
1.894
+0.034
+1.81%
Opening 14:43 05/20 EDT
OPEN
1.850
PREV CLOSE
1.860
HIGH
1.913
LOW
1.795
VOLUME
17.21K
TURNOVER
--
52 WEEK HIGH
6.02
52 WEEK LOW
1.430
MARKET CAP
26.46M
P/E (TTM)
-1.2254
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CALC last week (0512-0516)?
Weekly Report · 1d ago
Analysts Offer Insights on Healthcare Companies: CalciMedica (CALC), Enliven Therapeutics (ELVN) and Sanara MedTech (SMTI)
TipRanks · 5d ago
CalciMedica GAAP EPS of -$0.36 misses by $0.06
Seeking Alpha · 6d ago
CalciMedica Q1 EPS $(0.36) Misses $(0.31) Estimate
Benzinga · 6d ago
CALCIMEDICA REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CLINICAL & CORPORATE UPDATES
Reuters · 6d ago
CALCIMEDICA INC: QTRLY LOSS PER SHARE $0.36
Reuters · 6d ago
CALCIMEDICA INC: CASH POSITION EXPECTED TO FUND OPERATIONS INTO MID-2026
Reuters · 6d ago
*CalciMedica 1Q Loss/Shr 36c >CALC
Dow Jones · 6d ago
More
About CALC
CalciMedica, Inc. is a clinical-stage biopharmaceutical company. The Company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for inflammatory and immunologic diseases. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase IIb trial (called CARPO) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase I/II asparaginase-induced pancreatic toxicity (AIPT) study (called CRSPA).

Webull offers Calcimedica Inc stock information, including NASDAQ: CALC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CALC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CALC stock methods without spending real money on the virtual paper trading platform.